BioCentury
ARTICLE | Company News

Spectrum Pharmaceuticals, Servier deal

February 1, 2016 8:00 AM UTC

Spectrum granted Servier’s Servier Canada Inc. affiliate exclusive, Canadian rights to develop and commercialize four cancer drugs. The deal covers Zevalin ibritumomab for follicular B cell non-Hodgk...